Peptides

Thymosin Beta-4 (TB-500): What the Research Actually Shows

A naturally occurring protein with a real place in pharmaceutical development, real human trial data, and an anti-fibrotic signal now emerging independently in three different organ systems, sold in the peptide market under a different name, as a much smaller synthetic fragment that carries the parent protein's reputation without carrying its evidence.

What It Is

One Protein, and a Fragment Sold Under a Different Name

Thymosin beta-4 is a small protein found throughout the body that plays a central role in regulating actin, the structural protein cells use to change shape and move. It's gone through actual pharmaceutical development: RegeneRx Biopharmaceuticals studied the full-length protein as a topical gel and an injectable formulation for wound healing, and the World Health Organization assigned it the official name "timbetasin" in 2018. The human trials below, and the mouse mechanism studies, all used this full-length, 43-residue molecule.

What's sold in the peptide market as "TB-500" is not that molecule. Analytical chemistry work done for doping-control testing has identified commercial TB-500 as a synthetic seven-amino-acid fragment, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, corresponding to a specific active region (residues 17 through 23) of the full protein, with an acetyl group added to the end. The fragment is about a fifth the size of the native protein by molecular weight, and is missing a methionine the full-length protein has. So "TB-500" and thymosin beta-4 are related the way a fragment of a protein is related to the whole protein, not the way two brand names for the same drug are related, and nearly every piece of human evidence discussed when people talk about "TB-500" was actually generated using the full-length protein. That distinction is the organizing fact of this guide: understanding thymosin beta-4's real evidence base means understanding which molecule each finding below actually applies to.

How Strong Is the Evidence

Evidence Summary

At a Glance
Mechanism confidence Well-established for the native, full-length protein, on two separate fronts. The original, best-characterized mechanism is actin regulation: thymosin beta-4 is the primary protein keeping actin, the building block of the cell's internal skeleton, in its unpolymerized (monomer) form inside resting cells. A second mechanism has been emerging more recently: an anti-fibrotic effect, most directly tied to suppressing TGF-β-driven signaling, now independently demonstrated in mouse models of liver fibrosis, cardiac fibrosis, and intestinal fibrosis by three separate research groups. Three unrelated labs landing on the same anti-fibrotic direction in three different organs is a genuinely encouraging, convergent signal, and a real reason this mechanism deserves testing in the fibrotic conditions it hasn't reached yet.
Human data Three placebo-controlled trials now exist, all using the full-length native protein, not the fragment sold as TB-500. Two are topical: one (venous leg ulcers) shows a modest positive signal at a specific dose, the other (epidermolysis bullosa) was stopped early and showed no benefit over placebo. The third is new and considerably more significant: a 2025 randomized, double-blind, placebo-controlled trial of intravenous recombinant human thymosin beta-4 in 96 heart attack patients found a significant reduction in infarct size among patients treated early after their procedure, though the full study group did not reach significance overall, a timing-dependent result worth watching rather than a settled one. No human trial of any kind has evaluated either molecule for the soft-tissue or musculoskeletal injury recovery that TB-500 is most commonly marketed for.
Specific-condition claims Musculoskeletal injury recovery, tendon and ligament healing, and general "systemic recovery" claims common in TB-500 marketing are not supported by any human trial data for either molecule. The anti-fibrotic and macrophage-reprogramming findings below are real and encouraging, but so far demonstrated only in liver, heart, and gut disease models in mice, not in the conditions TB-500 is typically marketed for, and not yet in any human fibrotic-disease trial.
The Evidence

Two Real Mechanisms, a Growing Anti-Fibrotic Signal, and a New Human Cardiac Trial

Mechanism: Regulating the Cell's Actin Skeleton

Cassimeris L, Safer D, Nachmias VT, Zigmond SH. "Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes." The Journal of Cell Biology. 1992;119:1261-1270. doi: 10.1083/jcb.119.5.1261. This study established that full-length thymosin beta-4 is the primary protein sequestering G-actin (the unassembled, monomer form of actin) inside resting human white blood cells, at a substantial concentration (roughly 149 micromolar). The amount of actin bound up by thymosin beta-4 decreases when the cell is stimulated to move, consistent with a role in releasing actin monomers for polymerization when a cell needs to change shape or migrate. This is foundational, well-replicated cell biology, and it is specific to the full-length, native protein, not the seven-amino-acid fragment sold commercially as TB-500.

Human Cell (Leukocyte) Biochemistry Study · Endpoint: G-Actin Sequestration, Basic Mechanism, Not a Clinical or Behavioral Outcome

Animal Data: Cardiac Repair in Mice

Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432:466-472. doi: 10.1038/nature03000. In mice, full-length thymosin beta-4 promoted migration and survival of heart muscle cells and blood vessel cells, activated a specific intracellular survival pathway, and improved measured heart function after the mice underwent surgical coronary artery ligation (a standard heart-attack model). This is a well-cited and mechanistically detailed paper, but it is mouse-only data and concerns cell migration and survival rather than the fibrosis mechanism described below.

Mouse Model, Cardiac · Endpoint: Post-Infarct Cardiac Function and Cell Migration/Survival, Full-Length Protein, Rodent Only

Human Trial: Venous Leg Ulcers (Modest Positive Signal)

Guarnera G, DeRosa A, Camerini R. "Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing." Annals of the New York Academy of Sciences. 2007;1112:407-412. doi: 10.1196/annals.1415.003. Guarnera G, Bianchi L, Cardillo Piccolino F, et al. "The effect of thymosin treatment of venous ulcers." Annals of the New York Academy of Sciences. 2010;1194:207-212. doi: 10.1111/j.1749-6632.2010.05490.x. This randomized, double-blind, placebo-controlled trial (3-to-1 treatment-to-placebo ratio, roughly 72-73 patients across multiple European sites) tested topical full-length thymosin beta-4 gel, applied alongside standard wound debridement and compression, for chronic venous leg ulcers. The 0.03% dose showed a modest positive signal, described by the investigators as having "the potential to accelerate wound healing," with roughly a quarter of small-to-moderate ulcers achieving complete healing within three months. Safety was reported as comparable to placebo. This is real, randomized, placebo-controlled human evidence, but it is modest in size, specific to one dose and one wound type, and, again, uses the full-length native protein rather than the fragment marketed as TB-500.

Human RCT, Venous Leg Ulcers (n≈72-73) · Endpoint: Complete Wound Healing at 3 Months, Full-Length Protein, Modest Positive Signal at One Dose

Human Trial: Epidermolysis Bullosa (No Benefit, Terminated Early)

ClinicalTrials.gov. NCT00311766: "Study of RGN-137 Topical Gel in Patients With Dystrophic and Junctional Epidermolysis Bullosa." This randomized, double-blind, placebo-controlled Phase 2 trial (30 patients, 22 receiving one of three concentrations of topical full-length thymosin beta-4 gel, 8 receiving placebo) tested the same class of drug for a different skin condition, epidermolysis bullosa, a genetic blistering disorder. The trial was terminated early for reasons related to patient availability and drug expiration, and the available results showed no statistically significant benefit at 56 days, 5 of 8 placebo-treated wounds healed compared with 8 of 22 drug-treated wounds, numerically favoring placebo. This is an important negative data point and belongs in any honest accounting of what this molecule has and hasn't shown, even though it concerns full-length thymosin beta-4 rather than the TB-500 fragment.

Human RCT, Epidermolysis Bullosa (n=30) · Endpoint: Wound Healing at 56 Days, Full-Length Protein, No Significant Benefit, Terminated Early

What "TB-500" Actually Is, Chemically

Ho ENM, Kwok WH, Lau MY, et al. "Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry." Journal of Chromatography A. 2012;1265:57-69. doi: 10.1016/j.chroma.2012.09.043. This analytical chemistry paper, developed for equine anti-doping testing, directly characterizes what commercial "TB-500" is: a synthetic peptide reproducing the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln (positions 17-23 of thymosin beta-4), acetylated at the N-terminus, marketed as "TB-500." The paper's own framing describes it as "a synthetic version of an active region" of the parent protein, explicitly distinguishing it from the full-length molecule. This is the source that resolves the identity question at the center of this guide: the seven-amino-acid fragment described here, not the 43-residue protein studied in the clinical trials above, is what "TB-500" refers to as a commercial product.

Analytical Chemistry / Doping-Control Study · Endpoint: Structural Identification of Commercial TB-500 as a Thymosin Beta-4 Fragment, Not the Full-Length Protein

Mechanism: A Second Pathway, Suppressing Fibrosis in the Liver

Li H, Li Q, Zhang X, Zheng X, Zhang Q, Hao Z. "Thymosin β4 suppresses CCl4-induced murine hepatic fibrosis by down-regulating transforming growth factor β receptor-II." Journal of Gene Medicine. 2018;20(9):e3043. doi: 10.1002/jgm.3043. In mice with chemically induced liver fibrosis, thymosin beta-4 reduced fibrotic scarring by down-regulating the receptor that TGF-β, one of the body's central pro-fibrotic signals, uses to drive collagen-producing cells. This is the clearest mechanistic demonstration that thymosin beta-4 can interrupt fibrosis formation directly at the signaling level, not just at the wound-healing level described above, and it's a real reason to take the cardiac and intestinal findings below as a genuine pattern rather than three isolated coincidences.

Mouse Model, Chemically Induced Hepatic Fibrosis · Endpoint: Fibrosis Severity and TGF-β Receptor-II Expression, Full-Length Protein, Rodent Only

Animal Data: Protecting the Heart from Fibrosis After a Heart Attack

Wang F, He Y, Yao N, Ruan L, Tian Z. "Thymosin β4 protects against cardiac damage and subsequent cardiac fibrosis in mice with myocardial infarction." Cardiovascular Therapeutics. 2022;2022:1308651. doi: 10.1155/2022/1308651. In mice given a viral vector to boost thymosin beta-4 expression after an induced heart attack, the treated hearts showed less oxidative damage, less inflammation, better measured heart function, and, notably, less fibrosis than untreated hearts. At the cellular level, thymosin beta-4 reduced the growth of cardiac myofibroblasts, the cells responsible for laying down scar tissue, and blunted their activation by TGF-β1 specifically, the same signaling family implicated in the liver finding above. Two different labs, two different organs, two different induction methods, and the same TGF-β-linked anti-fibrotic direction is a genuinely encouraging convergence, and it's the direct reason a real cardiac fibrosis question was worth testing in people, which is exactly what the next study did.

Mouse Model, Myocardial Infarction · Endpoint: Cardiac Fibrosis, Myofibroblast Activation, and TGF-β1 Signaling, Full-Length Protein, Rodent Only

Human Trial: A Randomized Cardiac Trial in Heart Attack Patients

Zhang Y, Dong Q, Bian X, et al. "Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion." Cardiovascular Research. 2025;121(17):2747-2758. doi: 10.1093/cvr/cvaf223. PMID: 41229390. This is the most significant human data point in this guide. In mice, recombinant human thymosin beta-4 prevented cardiac dysfunction and fibrosis 28 days after an induced heart attack, working through a specific cardioprotective signaling pathway (ErbB2/Raf1) that, when blocked, eliminated the benefit, good evidence the effect is mechanism-specific rather than incidental. The same team then ran a randomized, double-blind, placebo-controlled trial in 96 people with acute ST-elevation heart attacks undergoing emergency stenting, 43 receiving recombinant human thymosin beta-4 within 8 hours of the procedure and 53 receiving placebo, followed for 90 days. Patients treated earliest showed a significant reduction in infarcted heart tissue at 90 days compared to placebo. Across the full group of 96 patients, the difference did not reach statistical significance, suggesting the timing of treatment after reperfusion may be the deciding factor rather than the drug not working. This is genuine, randomized, placebo-controlled human evidence that a real cardiac benefit is plausible and worth confirming in a larger, timing-optimized trial, not yet proof of a reliable clinical effect.

Human RCT, Acute STEMI Post-PCI (N=96) · Endpoint: Infarct Size at 90 Days, Recombinant Full-Length Protein, Positive in Early-Treated Subgroup, Not Significant Overall

Animal Data: Reprogramming Inflammatory Cells in Fatty Liver Disease

Zhu Z, Liao Y, Mou Q, Liu H, Shen Y, Zhu L, Cong S. "Thymosin β4 regulates tissue inflammatory response in mouse nonalcoholic fatty liver disease by promoting macrophage M2-type polarization." Journal of Inflammation Research. 2025;18:5791-5809. doi: 10.2147/JIR.S492814. PMID: 40322536. In a mouse model of fatty liver disease, thymosin beta-4 shifted liver macrophages away from their pro-inflammatory (M1) state and toward their repair-oriented (M2) state, reducing liver cell death in the process; when the researchers removed macrophages from the picture entirely, thymosin beta-4's protective effect disappeared, confirming that this immune-cell shift is how the benefit happens, not a side observation. This adds a second, independent mechanism, alongside the anti-fibrotic signaling above, by which thymosin beta-4 could plausibly support tissue repair in an inflammatory disease state; it's real evidence of a repair-promoting immune effect, demonstrated so far in one organ and one disease model.

Mouse Model, Diet-Induced Fatty Liver Disease · Endpoint: Macrophage M1-to-M2 Polarization and Hepatocyte Protection, Full-Length Protein, Rodent Only

Animal Data: Reducing Intestinal Fibrosis in a Colitis Model

Zhao TR, Hu EB, Wang MW, et al. "Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling." Molecular Biomedicine. 2026;7:140. doi: 10.1186/s43556-026-00539-9. PMID: 42606759. In mice with chemically induced colitis, oral recombinant human thymosin beta-4 improved survival, reduced weight loss, reduced intestinal inflammation, and, importantly, reduced intestinal fibrosis and collagen buildup, the process behind the strictures seen in longstanding inflammatory bowel disease. The mechanism identified here is suppression of a different signaling receptor (the mineralocorticoid receptor) than the TGF-β pathway implicated in the liver and heart findings above; the authors themselves note that how this connects to TGF-β signaling isn't yet worked out and needs further study. The researchers also found that mice bred to lack thymosin beta-4 did worse with colitis, and separately analyzed tissue from people with Crohn's disease and ulcerative colitis as part of the paper's background work, though the treatment itself was only tested in the general mouse colitis model, not a Crohn's-specific one. Put together with the liver and heart findings, this is now a third organ system where boosting or preserving thymosin beta-4 activity has reduced fibrosis in an animal model, even though the exact mechanism connecting all three isn't fully mapped yet, real support for testing this systematically in a fibrotic intestinal disease rather than a single-organ curiosity.

Mouse Model, Chemically Induced Colitis · Endpoint: Intestinal Fibrosis, Collagen Deposition, and Mineralocorticoid Receptor Signaling, Recombinant Full-Length Protein, Rodent Only
Honest Limits

What the Research Doesn't Yet Show

No human clinical trial of any kind has tested the seven-amino-acid fragment sold commercially as TB-500. Every placebo-controlled human trial identified for this guide used full-length or recombinant full-length thymosin beta-4, a structurally distinct, much larger molecule developed as an investigational drug under different formulations and names. No trial, in any species, has evaluated either molecule for musculoskeletal injury, tendon or ligament healing, or general physical recovery, the indications TB-500 is most commonly marketed for.

The anti-fibrotic mechanism is genuinely encouraging, three separate research groups finding the same direction in liver, heart, and gut is not something that happens by chance, but it remains animal data in all three organs, with human confirmation so far limited to the cardiac trial above, and that trial's overall result did not reach significance across the full patient group. No study of any kind, mechanistic or otherwise, has evaluated thymosin beta-4 or TB-500 for endometriosis, peritoneal adhesions, or post-surgical recovery; those remain unstudied rather than promising, and don't belong in the same conversation as the fibrosis findings above until an actual study exists.

Investigational, not FDA-approved for any indication except as noted in the trials above.

Where This Fits

How This Fits the Cellular Medicine Framework

Thymosin beta-4 is the clearest example this Knowledge Center has encountered of why this framework insists on verifying a compound's actual identity before evaluating its evidence, not just checking whether studies exist that mention a related name. The full-length protein went through legitimate drug development and produced real, if modest and mixed, human trial data, and a much smaller fragment of that same protein was given a commercial name, "TB-500," that lets marketing borrow the parent protein's clinical track record. Both molecules trace to the same biology, actin regulation and tissue repair signaling sit squarely at the cell-signaling level this framework is built around, but tracing to the same biology is not the same as being the same compound with the same evidence behind it. The discipline here is the same one applied throughout this Knowledge Center: verify what a molecule actually is and what was actually studied, rather than accepting a name, a family resemblance, or a widely repeated claim at face value.

The emerging anti-fibrotic signal is a second, useful illustration of how this framework treats a genuinely early finding: three independent research groups converging on the same direction, in three different organs, is real reason for optimism and real justification for the next trial, even while none of it has yet produced the kind of confirmed human outcome that would move it out of the mechanism-and-animal-data stage.

See the Full Framework
Sources

References

Cited on This Page
  1. Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119:1261-1270. doi:10.1083/jcb.119.5.1261 · PMID: 1447300
  2. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466-472. doi:10.1038/nature03000 · PMID: 15565145
  3. Guarnera G, DeRosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci. 2007;1112:407-412. doi:10.1196/annals.1415.003 · PMID: 17495250
  4. Guarnera G, Bianchi L, Cardillo Piccolino F, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. doi:10.1111/j.1749-6632.2010.05490.x · PMID: 20536470
  5. ClinicalTrials.gov. NCT00311766: Study of RGN-137 Topical Gel in Patients With Dystrophic and Junctional Epidermolysis Bullosa. clinicaltrials.gov/study/NCT00311766
  6. Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043 · PMID: 23084823
  7. Li H, Li Q, Zhang X, Zheng X, Zhang Q, Hao Z. Thymosin β4 suppresses CCl4-induced murine hepatic fibrosis by down-regulating transforming growth factor β receptor-II. J Gene Med. 2018;20(9):e3043. doi:10.1002/jgm.3043 · PMID: 29972714
  8. Wang F, He Y, Yao N, Ruan L, Tian Z. Thymosin β4 protects against cardiac damage and subsequent cardiac fibrosis in mice with myocardial infarction. Cardiovasc Ther. 2022;2022:1308651. doi:10.1155/2022/1308651
  9. Zhang Y, Dong Q, Bian X, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758. doi:10.1093/cvr/cvaf223 · PMID: 41229390
  10. Zhu Z, Liao Y, Mou Q, Liu H, Shen Y, Zhu L, Cong S. Thymosin β4 regulates tissue inflammatory response in mouse nonalcoholic fatty liver disease by promoting macrophage M2-type polarization. J Inflamm Res. 2025;18:5791-5809. doi:10.2147/JIR.S492814 · PMID: 40322536
  11. Zhao TR, Hu EB, Wang MW, Zhai YF, Mao YY, Hou WY, Zhang XZ, Liu ZZ, Hou SL, Xu JJ, Yu R. Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling. Mol Biomedicine. 2026;7:140. doi:10.1186/s43556-026-00539-9 · PMID: 42606759
See the Framework Applied

Explore the Rest of the Knowledge Center

Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.

Explore the Knowledge Center